Galapagos is seeking $338m via a US public offering to fund Phase III studies for its lead drug filgotinib in various new immunology and inflammation indications. The biotech will also use the cash to prepare for its evolution into a commercial organization in the next few years, when it hopes to start promoting the drug in Europe for the treatment of rheumatoid arthritis. Ultimately it wants to be a major European biotech leader.
Galapagos NV, listed on Nasdaq, has launched a US public offering totaling $338m in gross proceeds that will be used to build up a commercial unit in time for its first drug launch, expected for lead product filgotinib as a treatment for rheumatoid arthritis in the next few years.
The Belgium-based company will also use the cash to fund several new Phase III studies, with its partner Gilead...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
